Medicare Must Not Cost Shift Alzheimer’s Care to Medicaid
NAMD explains the serious cost implications of Medicare’s coverage decision on the Alzheimer’s drug Aduhelm for state Medicaid programs.
Author
- Jack Rollins, Director of Federal Policy
Focus Areas
Program Stream
In a controversial decision, the Food and Drug Administration recently approved Aduhelm, a drug intended to treat Alzheimer’s disease. Now Medicare must decide if it will cover the drug, and its decision has significant cost implications for state Medicaid programs. If Medicare does not cover it and Medicaid becomes the primary source of coverage, NAMD estimates Medicaid spending for Aduhelm could increase by 250 percent or more. In this blog, NAMD’s Director of Federal Policy explains these potential implications.
Related resources
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program's inflationary rebates.
How Can States Better Serve Dually Eligible Populations?
Episode 3 of Season 5 of the Medicaid Leadership Exchange offers insight on Medicaid and dual eligible members.
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.